BamSEC and AlphaSense Join Forces
Learn More

Onyx Pharmaceuticals Inc

Formerly NASDAQ: ONXX
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.2
from SC TO-C 130 pages Master Repurchase Agreement September 1996 Version Dated as Of: August 24, 2013 Between: AMGEN Inc., as “Seller” And: Bank of America, N.A., as “Buyer” 1. Applicability
12/34/56
EX-10.1
from SC TO-C 27 pages Project Nike Commitment Letter
12/34/56
EX-10.10.40
from 8-K 5 pages Onyx Pharmaceuticals, Inc. 2013 Cash Performance Incentive Plan Adopted: March 26, 2013 Approved by the Stockholders: May 23, 2013
12/34/56
EX-10.13(I)
from 8-K 32 pages Onyx Pharmaceuticals, Inc. 2005 Equity Incentive Plan Adopted by the Board of Directors: April 18, 2005 Approved by the Stockholders: June 1, 2005 Last Amended: March 26, 2013 Last Approved by the Stockholders: May 23, 2013 Termination Date: April 17, 2020
12/34/56
EX-10.7
from 8-K 9 pages Onyx Pharmaceuticals, Inc. Employee Stock Purchase Plan Adopted March 26, 1996 Approved by the Stockholders: April 30, 1996 Last Amended: March 26, 2013 Last Approved by the Stockholders: May 23, 2013
12/34/56
EX-10.39
from 10-Q 4 pages Material contract
12/34/56
EX-10.36(II)
from 10-Q 94 pages Amended and Restated License, Development and Commercialization Agreement Dated as of March 31, 2013 by and Among Onyx Pharmaceuticals, Inc. and Onyx Therapeutics, Inc. and Ono Pharmaceutical Co., Ltd
12/34/56
EX-10.23(III)
from 10-Q 14 pages March 12, 2013 John Osborn C/O Onyx Pharmaceuticals, Inc. 249 E. Grand Avenue South San Francisco, Ca 94080 Re: Separation Agreement
12/34/56
EX-10.23(II)
from 10-K 1 page Material contract
12/34/56
EX-10.18
from 10-K 35 pages Contract Manufacturing and Supply Agreement by and Among Dsm Pharmaceuticals, Inc., Onyx Pharmaceuticals, Inc., and Onyx Pharmaceuticals International Gmbh
12/34/56
EX-10.16
from 10-K 38 pages Contract Manufacturing Agreement Among Onyx Pharmaceuticals, Inc., Onyx Pharmaceuticals International Gmbh and Cambridge Major Laboratories, Inc. Confidential
12/34/56
EX-10.15
from 10-K 25 pages Contract Manufacturing Agreement
12/34/56
EX-10.19
from 8-K ~5 pages Base Salaries for Fiscal Year 2013 and Cash Bonuses for Fiscal Year 2012 for Certain Named Executive Officers
12/34/56
EX-10.24(II)
from 10-Q 1 page Material contract
12/34/56
EX-10.24(I)
from 10-Q 3 pages Material contract
12/34/56
EX-10.23
from 10-Q 3 pages May 18, 2012 John Osborn Dear John
12/34/56
EX-10.9(IV)
from 10-Q 21 pages Amendment No. 1 to Amended and Restated Executive Change in Control Severance Benefits Agreement
12/34/56
EX-10.13(I)
from 8-K 34 pages Onyx Pharmaceuticals, Inc. 2005 Equity Incentive Plan Adopted by the Board of Directors: April 18, 2005 Approved by the Stockholders: June 1, 2005 Most Recently Amended by the Board of Directors: March 21, 2012 Most Recently Approved by the Stockholders: May 21, 2012 Termination Date: April 17, 2015
12/34/56
EX-10.30(II)
from 10-Q 33 pages [ * ] = Certain Confidential Information Contained in This Document, Marked by Brackets, Has Been Omitted and Filed Separately With the Securities and Exchange Commission Pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as Amended
12/34/56
EX-10.38
from 10-K 70 pages Lease Agreement
12/34/56